264 related articles for article (PubMed ID: 28163245)
1. Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways.
Górowska-Wójtowicz E; Hejmej A; Kamińska A; Pardyak L; Kotula-Balak M; Dulińska-Litewka J; Laidler P; Bilińska B
Toxicol In Vitro; 2017 Apr; 40():324-335. PubMed ID: 28163245
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyflutamide affects connexin 43 via the activation of PI3K/Akt-dependent pathway but has no effect on the crosstalk between PI3K/Akt and ERK1/2 pathways at the Raf-1 kinase level in primary rat Sertoli cells.
Chojnacka K; Zarzycka M; Hejmej A; Mruk DD; Gorowska E; Kotula-Balak M; Klimek M; Bilinska B
Toxicol In Vitro; 2016 Mar; 31():146-57. PubMed ID: 26437446
[TBL] [Abstract][Full Text] [Related]
3. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
[TBL] [Abstract][Full Text] [Related]
4. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
5. Naringenin-Induced Apoptotic Cell Death in Prostate Cancer Cells Is Mediated via the PI3K/AKT and MAPK Signaling Pathways.
Lim W; Park S; Bazer FW; Song G
J Cell Biochem; 2017 May; 118(5):1118-1131. PubMed ID: 27606834
[TBL] [Abstract][Full Text] [Related]
6. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines.
Dizeyi N; Hedlund P; Bjartell A; Tinzl M; Austild-Taskén K; Abrahamsson PA
Urol Oncol; 2011; 29(4):436-45. PubMed ID: 19926313
[TBL] [Abstract][Full Text] [Related]
7. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
9. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
[TBL] [Abstract][Full Text] [Related]
10. Coumestrol Inhibits Proliferation and Migration of Prostate Cancer Cells by Regulating AKT, ERK1/2, and JNK MAPK Cell Signaling Cascades.
Lim W; Jeong M; Bazer FW; Song G
J Cell Physiol; 2017 Apr; 232(4):862-871. PubMed ID: 27431052
[TBL] [Abstract][Full Text] [Related]
11. Sinodielide A exerts thermosensitizing effects and induces apoptosis and G2/M cell cycle arrest in DU145 human prostate cancer cells via the Ras/Raf/MAPK and PI3K/Akt signaling pathways.
Hatashita M; Taniguchi M; Baba K; Koshiba K; Sato T; Jujo Y; Suzuki R; Hayashi S
Int J Mol Med; 2014 Feb; 33(2):406-14. PubMed ID: 24285252
[TBL] [Abstract][Full Text] [Related]
12. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
13. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
14. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
[TBL] [Abstract][Full Text] [Related]
15. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
16. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
Benitez DA; Pozo-Guisado E; Clementi M; Castellón E; Fernandez-Salguero PM
Br J Cancer; 2007 May; 96(10):1595-604. PubMed ID: 17486135
[TBL] [Abstract][Full Text] [Related]
17. Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.
Deep G; Oberlies NH; Kroll DJ; Agarwal R
Oncogene; 2008 Jun; 27(28):3986-98. PubMed ID: 18332867
[TBL] [Abstract][Full Text] [Related]
18. Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells.
Siddiqui IA; Adhami VM; Afaq F; Ahmad N; Mukhtar H
J Cell Biochem; 2004 Feb; 91(2):232-42. PubMed ID: 14743383
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk Between MAPK/ERK and PI3K/AKT Signal Pathways During Brain Ischemia/Reperfusion.
Zhou J; Du T; Li B; Rong Y; Verkhratsky A; Peng L
ASN Neuro; 2015; 7(5):. PubMed ID: 26442853
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]